Concepts for increasing gentamicin release from handmade bone cement beads by Rasyid, Hermawan N et al.
508  Acta Orthopaedica 2009; 80 (5): 508–513
Open Access - This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, 
distribution, and reproduction in any medium, provided the source is credited
DOI 10.3109/17453670903389782
Background and purpose    Commercial gentamicin-loaded bone 
cement beads (Septopal) constitute an effective delivery system 
for local antibiotic therapy. These beads are not available in all 
parts  of  the  world,  and  are  too  expensive  for  frequent  use  in 
others. Thus,  orthopedic  surgeons  worldwide  make  antibiotic-
loaded beads themselves. However, these beads are usually not as 
effective as the commercial beads because of inadequate release 
kinetics. Our purpose was to develop a simple, cheap, and effec-
tive formulation to prepare gentamicin-loaded beads with release 
properties and antibacterial efficacy similar to the commercially 
ones.
Methods  Acrylic beads were prepared with variable monomer 
content: 100% (500 µL/g polymer), 75%, and 50% to increase 
gentamicin  release  through  creation  of  a  less  dense  polymer 
matrix. Using the optimal monomer content, different gel-form-
ing polymeric fillers were added to enhance the permeation of 
fluids into the beads. Polyvinylpyrrolidone (PVP) 17 was selected 
as a suitable filler; its concentration was varied and the antibiotic 
release and antibacterial efficacy of these beads were compared 
with the corresponding properties of the commercial ones. 
Results   Gentamicin release rate and the extent of release from 
beads prepared with 50% monomer increased when the PVP17 
content was increased. Beads with 15 w/w% PVP17 released 87% 
of their antibiotic content. This is substantially more than the gen-
tamicin release from Septopal beads (59%). Acrylic beads with 15 
w/w% PVP17 reduced bacterial growth by up to 93%, which is 
similar to the antibacterial properties of the commercial ones.
Interpretation   A simple, cheap, and effective formulation and 
preparation process has been described for hand-made gentami-
cin-releasing acrylic beads, with better release kinetics and with 
antibacterial efficacy similar to that of the commercial ones.
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In Europe, commercially available gentamicin-loaded poly-
methylmethacrylate beads (Septopal) constitute an effective 
delivery system for local antibiotic therapy for osteomyelitis 
(Bucholz and Engelbrecht 1970, Blaha et al. 1990, Klemm 
1993), in combination with systemically delivered antibiot-
ics and surgical debridement. The gentamicin concentrations 
reached at the site of infection are far higher using antibiotic-
loaded bone cement beads than the concentrations achieved by 
systemic administration of the same antibiotic (Buchholz and 
Engelbrecht 1970), and far above the minimal inhibitory con-
centrations of most common pathogens (Wahlig et al. 1978). 
The use of antibiotic-loaded bone cement beads also gives 
very low antibiotic concentrations in serum and urine, thereby 
preventing toxic side effects (Diefenbeck et al. 2006). Alterna-
tives to PMMA beads have been investigated, such as plaster 
of Paris beads (Dacquet et al. 1992, Bowyer and Cumberland 
1994, Gaasbeek et al. 2005). Plaster of Paris is cheaper than 
bone cement and readily available, and small quantities can 
be used to make beads containing antibiotic. Plaster of Paris 
is tolerated when implanted into infected bone cavities, and 
is it absorbed over a period of weeks to months (Dacquet et 
al. 1992). Release rates from plaster of Paris beads are higher 
than from PMMA beads in the first 48 h (Bowyer and Cum-
berland 1994), but the release rates are much lower than from 
PMMA beads after this period. Since the PMMA beads work 
over a longer period of time (about 2 weeks), this paper will 
concentrate only on PMMA.
Gentamicin-loaded PMMA beads are not, however, com-
mercially available in several parts of the world, including the 
USA, and they are too expensive for common use in many 
other countries of the world. Thus, orthopedic surgeons world-
wide  make  antibiotic-loaded  beads  themselves,  sometimes 
using a template system, but most often by hand-rolling. The 
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on the penetration of dissolution fluids into the polymer matrix 
and subsequent diffusion of the dissolved drug from the beads. 
Both steps require a certain porosity of the cement. Commer- . Commer-
cially prepared gentamicin-loaded acrylic beads are porous 
and show much higher release rates than hand-rolled, non-
porous antibiotic-loaded acrylic beads (McLaren et al. 2004). 
Unfortunately, the exact method of pore production in these 
beads has not been disclosed.
In  order  to  increase  antibiotic  release  from  hand-rolled 
acrylic beads, McLaren et al. (2004, 2006, 2007a) proposed 
the addition of soluble fillers, such as glycin, xylitol, sucrose, 
or erythritol in order to increase their porosity and conse-
quently the penetration of the dissolution fluids. These soluble 
fillers have all increased the release of gentamicin from acrylic 
beads. Moreover, the amount of gentamicin release from an 
acrylic-glycine mixture increased with increasing amounts of 
glycine (McLaren et al. 2004). Furthermore, xylitol appeared 
to be more effective in increasing the amount of antibiotic 
release than glycine; for example, after 1 day, xylitol increased 
the release of daptomycin by a factor of 2.7 whereas glycine 
increased it 1.8 times as compared to beads without fillers (Mc 
Laren et al. 2006).
Although addition of these soluble fillers gave a doubling 
in antibiotic release from hand-rolled beads, the total release 
after 7 days remained limited to approximately 10% in the 
presence of soluble fillers, which is substantially inferior to the 
antibiotic release from commercially available beads (where 
the total release after 7 days amounts to around 60% of the 
total antibiotic content) (Walenkamp et al. 1986). Thus, the 
aim of this study was to develop a simple, cheap, and effective 
formulation and preparation process for acrylic beads with 
gentamicin release properties similar to those observed for 
commercially available beads. To this end, acrylic beads were 
first prepared with variable monomer content to give increased 
gentamicin release through the creation of a less dense poly-
mer matrix. Subsequently, after the optimal monomer con-
tent had been defined, different gel-forming polymeric fillers 
such as polyvinylpyrrolidone (PVP) (of 2 different molecular 
weights)  and  hydroxypropylmethylcellulose  (HPMC)  were 
added to enhance the permeability for dissolution of fluids 
and gentamicin release. After selection of the most favorable 
biodegradable filler, its concentration was varied and both the 
antibiotic release and the antibacterial efficacy of the final 
beads were compared with the release and efficacy of the com-
mercially available Septopal beads.
Materials and methods 
Commercially available antibiotic beads
Gentamicin-loaded  PMMA  beads,  which  are  commercially 
available  under  the  name  Septopal,  were  obtained  from 
Biomet Europe (Darmstadt, Germany). One bead (7.0 mm in 
diameter) contains 7.5 mg of gentamicin sulfate.
Preparation of beads with different concentrations of 
monomer
Simplex-P bone cement powder (Stryker Howmedica Osteon-
ics; Howmedica International, Limerick, Ireland) was mixed 
with  powdered  gentamicin  sulfate  (Gracia  Pharmaceuti-
cal, Indonesia) for 2 min in a ceramic bowl using a spatula. 
One gram of gentamicin sulfate was added to 40 g polymer 
powder. The resulting mixture was subsequently combined 
with 20 mL of monomer in a ceramic bowl and mixed for 2 
min with a spatula according to the manufacturer’s instruc-
tions. Beads thus prepared (500 µL/g polymer) will be termed 
“100% monomer”. In addition, beads were prepared with 75% 
and 50% of the prescribed amount of monomer (375 µL/g and 
250 µL/g polymer, respectively). The material was mixed until 
a doughy paste was obtained, and the gentamicin-PMMA-
MMA mixture was hand-rolled into beads. 
Preparation of beads with different polymeric fillers
Powdered  PMMA  and  gentamicin  sulfate  (1  g  gentamicin 
sulfate and 40 g PMMA powder) were mixed. Then one of 
the  polymeric  fillers  was  added  to  this  powder  mixture.  3 
biocompatible gel-forming polymeric fillers were used: poly-
vinylpyrrolidone with a molecular weight of 360 kDa (PVP 
90K)  (Genfarma,  Zaandam,  the  Netherlands),  polyvinyl-
pyrrolidone with a molecular weight of 7–11 kDa (PVP 17, 
Kollidon;  BASF,  Germany),  and  hydroxypropylmethylcel-
lulose  (HPMC;  Sigma-Aldrich  Chemie  GmbH,  Steinham, 
Germany). Polymeric fillers were mixed at a concentration of 
10 w/w% with respect to the amount of polymer powder. The 
resulting mixtures were finally combined with 50% (250 µL/g 
polymer) of the prescribed amount of monomer and the beads 
were prepared as described above. 
Preparation of beads with different concentrations of 
PVP 17
Powdered  PMMA  and  gentamicin  sulfate  (1  g  gentamicin 
sulfate and 40 g PMMA powder) were subsequently mixed 
with different amounts of PVP 17 (5 w/w%, 10 w/w%, and 
15 w/w% with respect to the amount of polymer powder) and 
beads were prepared with 50% monomer (250 µL/g polymer) 
as described above.
Analysis of the release kinetics of gentamicin from 
the beads
A gentamicin-loaded acrylic bead was immersed in 10 mL 
sterile phosphate-buffered saline (PBS) at pH 7.4 and incu-
bated at 37°C. At designated time intervals (6 and 24 h; and 2, 
3, 7, and 14 days), 500-µL aliquots of the gentamicin solution 
in PBS were taken and the total amount of buffer was restored 
to 10 mL. 
Gentamicin concentrations were measured using a proce-
dure described by Sampath and Robinson (1990). Briefly, an 
o-phthaldialdehyde reagent was made and stored for 24 h in 
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dehyde reagent, and isopropanol were mixed in equal pro-
portions and stored for 30 min at room temperature. The o-
phthaldialdehyde reacted with the gentamicin amino groups 
and chromophoric products were obtained, the absorbances of 
which were measured at 332 nm using a Genesys Spectronic 
20  spectrophotometer  (Spectronic  Instruments,  Rochester, 
NY). A calibration curve was used to calculate the gentamicin 
concentrations in the samples. The percentages of gentami-
cin released were calculated with respect to the total amount 
incorporated and compared with the gentamicin release from 
Septopal beads.
The release experiments with beads prepared with different 
concentrations of PVP 17 were performed in triplicate and a 
statistical analysis (Student’s t-test for independent samples) 
was done in order to compare the gentamicin release rates 
from the handmade beads with those from commercial Septo-
pal beads. A 95% (p < 0.05, 2-tailed) confidence interval was 
applied for statistical significance.
Scanning electron microscopy 
To compare the polymer matrix of our hand-rolled beads with 
that of Septopal beads, scanning electron microscopy (SEM) 
was performed. Examination was done at 2.0 kV in a JEOL 
field  emission  scanning  electron  microscope  type  6301F. 
Beads were sputter-coated with a 3-nm thick conductive layer 
of gold/ palladium (80/20).  
Analysis of the antibacterial efficacy of the beads 
3 hand-rolled or Septopal beads were each immersed in 5 mL 
tryptone soya broth (TSB; Oxoid Ltd., Cambridge, UK) and 
incubated at 37°C. Each bead was transferred on a daily basis 
to 5 mL fresh TSB and again incubated at 37°C, yielding broth 
containing antibiotic released over a 24-h period for biofilm 
growth studies. Only broth collected after 1, 2, 3, 7, and 14 
days  was  used  for  further  evaluation.  Elution  media  were 
stored in a refrigerator at 4°C until further use.
Biofilm formation is a key process in the development and 
persistence of osteomyelitis, and Staphylococcus aureus is a 
common cause of osteomyelitis. Thus, biofilms were grown 
using a clinical strain, S. aureus 5298, isolated from a patient 
with an implant-related osteomyelitis at the University Medi-
cal Center Groningen, the Netherlands. This strain was gen-
tamicin-sensitive, with an MIC value of 0.75 µg/mL. A pre-
culture of the strain was used to fill 96-well plates with 200 
µL bacterial suspension (2 µL preculture + 198 µL fresh TSB, 
or TSB collected as described above after antibiotic release 
from an immersed bead). Biofilms were grown for 24 h at 
37°C. Subsequently, the wells were flushed with 200 µL PBS 
to remove free-floating bacteria. Then, the wells were stained 
with 200 µL 1% crystal violet for 30 min, washed with 200 µL 
demineralized water to remove the excess stain, and the crys-
tal violet was solubilized in 200 µL of ethanol-acetone (80:20, 
v/v). The absorbance at 575 nm was subsequently determined 
using a microtiter plate reader and expressed as a percentage 
with respect to the absorbance of control biofilms grown in the 
absence of released antibiotics. All experiments were repeated 
3 times with separately grown bacteria. 
Statistical analysis was done in order to compare the antibac-
terial efficacy of the hand-rolled beads with that of Septopal 
beads. Differences were analyzed pair-wise for significance 
using Student’s t-test, with significance assumed at p-values 
≤ 0.05. 
Results  
Characteristics of the beads
The different hand-rolled beads had an average diameter of 
13 mm and their average weight was 1.45 g, 1.34 g, and 1.23 
g for beads prepared with 100%, 75%, and 50% monomer, 
respectively. 
Gentamicin release
Release of gentamicin from beads prepared with 100% mono-
mer leveled off within the time interval of the experiment, 
and was confined to about 8% of the total amount of genta-
micin included. Reduction of the amount of monomer caused 
incomplete polymerization and sintering of the polymer beads, 
which  resulted  in  an  almost  2-fold  increase  in  gentamicin 
release when 50% of monomer was employed, as compared to 
beads made with 100% monomer (Figure 1). 
Inclusion of a biodegradable filler almost tripled the amount 
of gentamicin release compared to its release in the absence of 
fillers. There was little difference in release rates between the 
different fillers (Figure 2).  
Based  on  the  observation  that  the  dissolution  of  HPMC 
created  a  sticky  and  viscous  medium,  which  was  difficult 
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Figure 1. Cumulative percentage of gentamicin release from PMMA 
beads made with 100%, 75%, or 50% monomer, as a function of time 
during exposure to phosphate-buffered saline (PBS). Acta Orthopaedica 2009; 80 (5): 508–513  511
to handle, and the fact that PVP 17 had the highest purity, 
we decided to vary the amount of PVP 17 (Figure 3) and 
to compare the gentamicin release kinetics of these cement 
beads with those of Septopal beads. The gentamicin release 
from beads prepared with 50% monomer increased when the 
amount of PVP 17 in the beads was increased. Beads contain-
ing 15 w/w% PVP 17 released 87% of their antibiotic con-
tent in 14 days. Importantly, this is significantly more than the 
gentamicin release from Septopal beads (p < 0.05), which is 
limited to only 59% after 14 days.
Evaluation of bead porosities by SEM
Beads prepared with 100% monomer formed a dense material 
with much mass and little porosity. Reduction of the amount 
of monomer relative to the prescribed amount caused a major 
increase in porosity, and the polymer particles appeared more 
“sintered” rather than “fused” together (Figure 4). 
Antibacterial efficacy 
Both bead systems showed high reductions in biofilm growth 
for up to 14 days after immersion (Figure 5). There was no sta-
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Figure 2. Cumulative percentage of gentamicin release from PMMA 
beads made without filler and with 10 w/w% of PVP 17, PVP 90K, or 
HPMC and 50% of the prescribed amount of monomer, as a function 
of time during exposure to PBS. 
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Figure 3. Cumulative percentage of gentamicin release from PMMA 
beads made with 5 w/w%, 10 w/w%, or 15 w/w% PVP 17 and 50% of 
the prescribed amount of monomer, as a function of time during expo-
sure to PBS, in comparison to the gentamicin release from commercial 
Septopal beads. Error bars denote the SD for 3 different beads of hand-
rolled and Septopal type. 
Figure 4. SEM micrographs of gentamicin-loaded, fractured acrylic beads: (A) prepared with the prescribed amount of monomer; (B) prepared with 
50% of the prescribed amount of monomer. The images were taken from the fracture side of the beads. Scale bars represent 100 µm for low- and 
high-magnification micrographs and for the insert. 
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tistically significant difference in biofilm inhibition between 
our hand-rolled beads and Septopal beads.  
Discussion
We  have  described  a  simple,  cheap,  and  effective  formu-
lation  and  preparation  process  for  gentamicin-releasing 
PMMA beads, with release kinetics that are somewhat better 
than  those  observed  for  commercially  available  Septopal 
beads. The improved release kinetics are mainly the result of 
increased porosity of the beads, due to the use of only 50% 
of the prescribed amount of monomer, which causes sintering 
rather than polymerization fusion of polymer particles, leav-
ing a porous matrix. Secondly, the addition of a gel-forming, 
water-soluble polymeric filler, PVP 17, ensures penetration of 
fluids into all parts of the matrix (full percolation), thereby 
increasing the total amount of drug that is released.
The efficiency of the polymerization reaction became less 
when the proportion of liquid monomer added to the poly-
meric bone cement powder was reduced. If the amount of 
monomer is insufficient for the reaction to occur at all pos-
sible contact sites of the polymer particles, a more porous 
matrix will be formed, allowing penetration of water to most 
sites in the beads. This will lead to a higher amount of genta-
micin being released (Frutos Cabanillas et al. 2000). On the 
other hand, with the reduction in the amount of monomer, the 
hardening time of the acrylic becomes considerably reduced 
(Pascual et al. 1999) and it requires some dexterity to prepare 
beads within the time available. Yet, it is possible to produce 
beads, although the last beads prepared out of a batch tend to 
appear brittle. In general, however, manual examination of the 
beads prepared with 50% monomer showed that they had suf-
ficient strength for this non-load-bearing application of bone 
cement. Reduction of the monomer content to below 50% was 
impossible, as no coherence could be obtained at these lower 
concentrations (Willert et al. 1979). 
The  use  of  gel-forming,  water-soluble  polymeric  fillers 
turned  out  to  be  indispensable  to  increase  the  gentamicin 
release to levels comparable to or higher than the release of 
gentamicin  by  the  commercially  available  Septopal  beads. 
Although we chose to use PVP 17 for this purpose, other bio-
degradable fillers might also have served the purpose. PVP 
17-filled beads showed excellent gentamicin release profiles, 
and the Kollidon PVP 17 PF grade is considered safe for par-
enteral use in humans (Böhler 1999). Moreover, the PVP 17 
could easily be combined with the acrylic polymer in the pro-
duction process. 
Several studies have been done to investigate the effect of 
biodegradable fillers on the drug release of antibiotic-loaded 
bone  cement.  Frutos  et  al.  (2002)  studied  the  influence  of 
PVP 12 on the antibiotic release from commercially avail-
able gentamicin-loaded bone cement. Incorporation of PVP 
into the cement matrix led to a remarkable increase in the 
maximum amount of gentamicin released, and this effect was 
proportional to the PVP concentration incorporated. Virto et 
al. (2003) studied the antibiotic release of gentamicin-loaded 
bone cement after addition of HPMC. HPMC did not pro-
duce an increase in the gentamicin release and these authors 
hypothesized that dissolution of HPMC creates a surrounding 
similar to a gel that makes gentamicin release from the cement 
matrix difficult. However, we found a distinct increase in the 
gentamicin release after addition of HPMC to bone cement, 
with the clear distinction that our bone cement was made with 
50% of the prescribed monomer. Also, McLaren et al. (2007a) 
investigated the use of biodegradable fillers but, like Frutos et 
al. (2002) and Virto et al. (2003), they did not use less mono-
mer, and thus no additional intrinsic porosity was created (i.e. 
porosity achieved without dissolution of any filler material). 
In line with our findings, McLaren et al. (2007a,b) showed 
that it is not the filler material that is crucial but rather its par-
ticle size, and fillers with a larger particle size led to larger 
pores,  less  pore  interconnectivity,  and  faster  fluid  penetra-
tion. Smaller-size particles led to smaller pores, greater pore 
interconnectivity, and smaller areas between the pores with no 
fluid penetration. 
The gentamicin-loaded beads based on the use of half the 
prescribed amount of monomer and the addition of gel-form-
ing polymeric filler reduced biofilm formation as effectively 
as commercially available Septopal beads. The (statistically 
insignificant) reduction in efficacy of our hand-rolled beads is 
presumably due to a less favorable area-to-volume ratio, as the 
hand-rolled beads were larger than the commercially available 
beads. Moreover, hand-rolled beads are usually not uniform 
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Figure 5. Biofilm inhibition (%) as a function of time, by different gen-
tamicin-releasing beads, calculated as a percentage UV absorbance 
with respect to a control, i.e. the absorbance of a biofilm grown in broth 
without antibiotics released from beads. Bars represent the mean ± SD 
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in size, giving much larger standard deviations than obtained 
with commercially available beads and attesting to the greater 
reproducibility of Septopal beads. To solve this problem, a 
beads template system could be used, in which antibiotic-
loaded beads of uniform size and small diameter could be pro-
duced. A template system should also be considered because 
of the short time available to prepare beads with half of the 
prescribed amount of monomer. 
To verify the significance of our in vitro observations, in 
vivo studies will be required that take into account both com-
plete  eradication  of  the  infection  and  the  time  required  to 
achieve this outcome, but we believe the results reported here 
support our hypothesis that acrylic beads containing half the 
prescribed amount of monomer and PVP may offer a thera-
peutic efficacy similar to that of commercially available Sep-
topal beads. Application of this novel formulation of acrylic 
beads  in  combination  with  a  bead-template  system  would 
be useful for three different groups of orthopedic surgeons, 
to make chains of antibiotic-loaded bone cement beads: (1) 
surgeons in countries where they are not allowed to import 
the Septopal beads, such as the USA; (2) surgeons in devel-
oping countries, since these beads are approximately 3 times 
cheaper than the commercial ones (apart from the costs of the 
template system); and (3) surgeons who are familiar with the 
use of the Septopal beads but who need to treat their patients 
with  another  antibiotic  because  of  the  increasing  number 
of patients infected with gentamicin-resistent bacteria. The 
method we describe here also makes it possible to create bone 
cement beads loaded with vancomycin, clindamycin, or other 
antibiotics that are not yet available commercially. 
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